CombiMatrix Shares up Sharply as Firm Reports Record Prenatal Testing Volumes in Preliminary Q1 Results | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of CombiMatrix rose as much as 25 percent today after the company said that it expects to report record volumes of prenatal testing for the first quarter.

The Irvine, Calif.-based firm said today that for the three months ended March 31, billable prenatal tests were up 124 percent year over year in preliminary results. Investors responded by driving shares up as high as $4.62, up from Wednesday's closing price of $3.46.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.